News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Momenta Pharmaceuticals, Inc. (MNTA) Release: First Patient Dosed With M402 in Phase 1/2 Clinical Trial in Metastatic Pancreatic Cancer


7/2/2012 9:28:19 AM

CAMBRIDGE, Mass., July 2, 2012 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that dosing has begun in the Phase 1/2 proof-of-concept clinical trial of M402 in combination with gemcitabine in patients with advanced metastatic pancreatic cancer.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES